Genetic polymorphism of drug metabolizing enzymes and estrogen receptor in pharmacogenetics of tamoxifen: implication for optimization of breast cancer treatment / Teh Lay Kek and Mohd Zaki Salleh

Introduction: Tamoxifen has been used as a hormonal therapy in breast cancer patients who are positive for estrogen receptor. The drug is metabolized by Cytochrome P450 2D6 (CYP2D6) into several metabolite. Variation in CYP2D6 activity has important therapeutic consequences and can play a significan...

Full description

Bibliographic Details
Main Authors:	Lay Kek, Teh, Salleh, Mohd Zaki
Format:	Research Reports
Language:	English
Published:	Research Management Institute (RMI) 2010
Subjects:	Materia medica
Online Access:	http://ir.uitm.edu.my/id/eprint/24806/ http://ir.uitm.edu.my/id/eprint/24806/1/LP_TEH%20LAY%20KEK%20RMI%2010_5.pdf

id	uitm-24806
recordtype	eprints
spelling	uitm-248062019-07-19T03:09:31Z http://ir.uitm.edu.my/id/eprint/24806/ Genetic polymorphism of drug metabolizing enzymes and estrogen receptor in pharmacogenetics of tamoxifen: implication for optimization of breast cancer treatment / Teh Lay Kek and Mohd Zaki Salleh Lay Kek, Teh Salleh, Mohd Zaki Materia medica Introduction: Tamoxifen has been used as a hormonal therapy in breast cancer patients who are positive for estrogen receptor. The drug is metabolized by Cytochrome P450 2D6 (CYP2D6) into several metabolite. Variation in CYP2D6 activity has important therapeutic consequences and can play a significant role in the development of adverse events or therapeutic failure in susceptible individuals. Beside, variation of drug transporter such as MDRl may alter the accumulation of the drug and cause toxicity in patients. Furthermore, the different expression of receptor-a and estrogen receptor-P may be associated with different therapy outcome. Materials and methods: In subject recruitment, patient samples were collected from HUKM, Hospital Selayang and HTAF. Patients who have received tamoxifen for treatment of breast cancer were recruited according to exclusion and inclusion criteria. Genotyping method for CYP2D6 and MDRl were developed using multiplex allele specific PCR (ASPCR) approach. DHPLC method was developed to detect existing and new alleles in CYP2D6 and estrogen receptors. The expression of estrogen receptor-a and estrogen receptor-p from samples would be quantitated using Real-time PCR. Result: The most common variants detected is CYP2D610 with 50% of heterozygous CYP2D61/10 and CYP2D65 with 7.8% was detected high in breast cancer patients. Furthermore CYP2D6l/4 and CYP2D6l/4 was detected but at low frequencies. Research Management Institute (RMI) 2010 Research Reports NonPeerReviewed text en http://ir.uitm.edu.my/id/eprint/24806/1/LP_TEH%20LAY%20KEK%20RMI%2010_5.pdf Lay Kek, Teh and Salleh, Mohd Zaki (2010) Genetic polymorphism of drug metabolizing enzymes and estrogen receptor in pharmacogenetics of tamoxifen: implication for optimization of breast cancer treatment / Teh Lay Kek and Mohd Zaki Salleh. [Research Reports] (Unpublished)
repository_type	Digital Repository
institution_category	Local University
institution	Universiti Teknologi MARA
building	UiTM Institutional Repository
collection	Online Access
language	English
topic	Materia medica
spellingShingle	Materia medica Lay Kek, Teh Salleh, Mohd Zaki Genetic polymorphism of drug metabolizing enzymes and estrogen receptor in pharmacogenetics of tamoxifen: implication for optimization of breast cancer treatment / Teh Lay Kek and Mohd Zaki Salleh
description	Introduction: Tamoxifen has been used as a hormonal therapy in breast cancer patients who are positive for estrogen receptor. The drug is metabolized by Cytochrome P450 2D6 (CYP2D6) into several metabolite. Variation in CYP2D6 activity has important therapeutic consequences and can play a significant role in the development of adverse events or therapeutic failure in susceptible individuals. Beside, variation of drug transporter such as MDRl may alter the accumulation of the drug and cause toxicity in patients. Furthermore, the different expression of receptor-a and estrogen receptor-P may be associated with different therapy outcome. Materials and methods: In subject recruitment, patient samples were collected from HUKM, Hospital Selayang and HTAF. Patients who have received tamoxifen for treatment of breast cancer were recruited according to exclusion and inclusion criteria. Genotyping method for CYP2D6 and MDRl were developed using multiplex allele specific PCR (ASPCR) approach. DHPLC method was developed to detect existing and new alleles in CYP2D6 and estrogen receptors. The expression of estrogen receptor-a and estrogen receptor-p from samples would be quantitated using Real-time PCR. Result: The most common variants detected is CYP2D610 with 50% of heterozygous CYP2D61/10 and CYP2D65 with 7.8% was detected high in breast cancer patients. Furthermore CYP2D6l/4 and CYP2D6l/4 was detected but at low frequencies.
format	Research Reports
author	Lay Kek, Teh Salleh, Mohd Zaki
author_facet	Lay Kek, Teh Salleh, Mohd Zaki
author_sort	Lay Kek, Teh
title	Genetic polymorphism of drug metabolizing enzymes and estrogen receptor in pharmacogenetics of tamoxifen: implication for optimization of breast cancer treatment / Teh Lay Kek and Mohd Zaki Salleh
title_short	Genetic polymorphism of drug metabolizing enzymes and estrogen receptor in pharmacogenetics of tamoxifen: implication for optimization of breast cancer treatment / Teh Lay Kek and Mohd Zaki Salleh
title_full	Genetic polymorphism of drug metabolizing enzymes and estrogen receptor in pharmacogenetics of tamoxifen: implication for optimization of breast cancer treatment / Teh Lay Kek and Mohd Zaki Salleh
title_fullStr	Genetic polymorphism of drug metabolizing enzymes and estrogen receptor in pharmacogenetics of tamoxifen: implication for optimization of breast cancer treatment / Teh Lay Kek and Mohd Zaki Salleh
title_full_unstemmed	Genetic polymorphism of drug metabolizing enzymes and estrogen receptor in pharmacogenetics of tamoxifen: implication for optimization of breast cancer treatment / Teh Lay Kek and Mohd Zaki Salleh
title_sort	genetic polymorphism of drug metabolizing enzymes and estrogen receptor in pharmacogenetics of tamoxifen: implication for optimization of breast cancer treatment / teh lay kek and mohd zaki salleh
publisher	Research Management Institute (RMI)
publishDate	2010
url	http://ir.uitm.edu.my/id/eprint/24806/ http://ir.uitm.edu.my/id/eprint/24806/1/LP_TEH%20LAY%20KEK%20RMI%2010_5.pdf
first_indexed	2023-09-18T23:13:24Z
last_indexed	2023-09-18T23:13:24Z
_version_	1777418952252588032

Genetic polymorphism of drug metabolizing enzymes and estrogen receptor in pharmacogenetics of tamoxifen: implication for optimization of breast cancer treatment / Teh Lay Kek and Mohd Zaki Salleh

Similar Items